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Abstract
This report focuses mainly on the major reduction of the risk of relapse of gastrointestinal stromal
tumor (GIST) treated with imatinib, as identified in the American College of Surgeons Oncology
Group (ACOSOG) Z9001 trial. It also focuses on the many unknowns associated with adjuvant
imatinib therapy despite approvals by the US Food and Drug Administration and the European
Medicines Agency, and on a new marker for the diagnosis of GIST.
Introduction and context
Imatinib mesylate (IM), a small-molecule tyrosine
kinase inhibitor, is the standard first-line treatment in
advanced gastrointestinal stromal tumor (GIST) disease.
Given the high risk of relapse following surgery for
localized GISTs, especially for larger tumors, and the
efficacy of IM in the advanced setting as well as its
favorable safety profile, investigators hypothesized that
IM given post-operatively after gross complete resection
of primary GISTs could delay or prevent recurrence and
therefore improve survival. Thus, three major rando-
mized trials have been investigating the role of a 400-mg
daily dose of IM, given for (a) 1 year versus placebo with
relapse-free survival (RFS) as the primary endpoint
(American College of Surgeons Oncology Group [ACO-
SOG] Z9001), (b) 2 years versus observation alone with
overall survival as the primary endpoint (Intergroup
GEIS/EORTC/ISG/FSG/AGITG 62024), or (c) 3 years
versus 1 year with RFS as the primary endpoint
(Scandinavian Sarcoma Group and the German Associa-
tion for Medical Oncology [SSG XVIII/AIO] trial). So far,
only the ACOSOG Z9001 trial results are available.
Recent advances
The ACOSOG Z9001 study enrolled 713 patients with a
localized GIST of greater than 3 cm in diameter [1].
Preliminary data showed a major reduction in the risk of
recurrence, from 17% to 2% at 1 year (P = 0.0001), with
a hazard ratio of 0.35. In the updated report [2], the
difference in RFS was significant for all tumor size
subgroups (i.e., 3-6 cm, 6-10 cm, and ≥10 cm). Adjuvant
IM was well tolerated. No significant impact on overall
survival was observed. At the ASCO GI (American Society
of Clinical Oncology – Gastrointestinal) meeting in
January 2010, Blackstein and colleagues [3] reported all
pathologic data (mitotic rate, size, and location of
tumor) that were available in 620 patients. The risk of
tumor recurrence was estimated using mitotic rate, size,
and location according to the classification scheme of
Miettinen and Lasota [4]. In the IM and placebo arms,
respectively, 2-year RFS rates were 98% versus 98%
(P = 0.92) for low-risk patients, 98% versus 76%
(P = 0.05) for moderate-risk patients, and 77% versus
41% (P < 0.0001) for high-risk patients. The question of
which patient population will most benefit from
adjuvant IM is of major importance.
Accurate risk stratification is crucial for the selection of
patients who are most likely to benefit from adjuvant IM
therapy in clinical practice. Recently, Gold and collea-
gues [5] developed and validated a nomogram to predict
RFS after resection of a localized primary GIST to help
guide patient selection for adjuvant IM therapy. The
nomogram, which takes into account tumor size (in
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mitoses per 50 high-power fields), has better predictive
accuracy, as determined by concordance probabilities,
than two commonly used staging systems developed at
the US National Institutes of Health GIST workshop in
2001 [6,7]. It has a concordance probability similar to
that of the third staging system, the Armed Forces
Institute of Pathology (AFIP)-Miettinen system [4].
Nomogram predictions of RFS seem better calibrated
than predictions made with the AFIP-Miettinen system.
Very recently, the MetaGIST (Gastrointestinal Stromal
Tumor Meta-Analysis Group) [8] published the final
data of the two large, randomized, cooperative group
studies comparing two doses of IM (400 mg daily versus
400 mg twice daily) in 1640 patients with advanced
GISTs and showed that the presence of KIT exon 9
mutations was the only significant predictive factor for
the benefit of high-dose therapy. They confirmed that
among patients with KIT exon 9 mutations, progression-
free survival (PFS) was significantly longer for patients
treated in the high-dose arm (P = 0.17).
Recently, Demetri et al. [9] reported for the first time a
relationship between IM exposure and clinical benefit
rates in patients with advanced/metastatic GIST. IM
plasma levels showed a high inter-patient variability, and
low IM plasma exposure (minimum concentration
[Cmin] <1100 ng/mL) showed a trend of low rate of
objective response and a rapid evolution of resistance
(short time to progression). These results suggest that a
minimal plasma threshold may be necessary to achieve
and maintain clinical response in GISTs and that a low
Cmin level of IM (i.e., <1100 ng/mL) might contribute to
drug failure in patients with advanced GISTs.
For the treatment of metastatic GISTs that are resistant to
both IM and sunitinib, Montemurro et al. [10] reported
the first results of nilotinib efficacy (400 mg twice a day)
in a compassionate use program. The median nilotinib
treatment duration was 10 weeks (2 days to 104 weeks),
and 21 patients (40%) were treated longer than 12
weeks. Five patients out of 52 (10%, 95% confidence
interval [CI] 2-18%) responded to nilotinib, and 19
(37%, 95% CI 24-50%) had disease stabilization. The
median PFS was 12 weeks (95% CI 9-15 weeks), and the
median overall survival was 34 weeks (95% CI 3-65
weeks). Nilotinib was well tolerated. These findings
suggest that nilotinib does have activity in these heavily
treated patients, as suggested in the phase I study [11].
Moreover, a major advance was reported in the diagnosis
of GIST in 2009. Miettinen et al. [12] found that DOG1
(discovered on GIST-1) antibody is as sensitive as c-kit
for the diagnosis of GISTs. The authors evaluated this
new marker (that was discovered on GIST expression
profiles) and c-kit on a large panel of tumors, including
GISTs (n = 1168) and other tumors (n = 672), and
normal tissues. The overall sensitivities of DOG1 and
c-kit are nearly identical (94.4% and 94.7%, respectively),
but DOG1 is slightly better in gastric epithelioid GISTs.
Negativity for both markers is observed in 2.6% of GISTs
of the gastrointestinal tract. DOG1 is highly specific for
GISTs, with a positivity of only 3% in other mesench-
ymal tumors but a positivity of 20% in gastrointestinal
carcinomas.
Agaimy et al. [13], like Agaram et al. [14] previously,
reported that V600E BRAF mutations are alternative early
molecular events in a subset (4-7%) of KIT/PDGFRA
wild-type GISTs. Agaimy et al. [13] demonstrated that the
V600E BRAF mutation may occur in early-stage inciden-
tal GISTs, and are associated with a very low risk of
malignant behaviour. These authors reported that muta-
tions in KIT, PDGFRA, and BRAF are mutually exclusive
in their study, and like Agaram et al. [14], they indicate
that BRAF-mutated GISTs show a predilection for the
small bowel.
Implications for clinical practice
IM has been reported to induce a major reduction of the
risk of relapse in the only adjuvant trial for which results
are yet available. However, we do not know yet whether
adjuvant IM prevents or merely delays relapse, whether it
will improve overall survival, or whether specific at-risk
populations or molecular subtypes should or should not
be offered treatment, and finally we do not yet know the
optimal duration of this treatment in these patients.
Accurate risk stratification is crucial for the selection of
patients who are most likely to benefit from adjuvant IM
therapy. The validated nomogram of Gold and collea-
gues [5] could be used to select these patients.
Pathologists should now include DOG1 in the panel of
markers for diagnosing GISTs. For patients with meta-
static GISTs, the knowledge of the mutational status
before starting treatment is useful in choosing the most
appropriate dose because patients with KIT exon 9
mutations, and only these patients, have a significantly
prolonged PFS when they start IM at 800 mg daily.
The results of the nilotinib compassionate program
suggest that nilotinib does have activity in these heavily
treated patients, but the results of the randomized phase
III trial, comparing nilotinib with best treatment accord-
ing to investigators in GIST patients resistant to both IM
and sunitinib, are eagerly awaited.
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relapse-free survival.
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